Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Human papilloma virus in oral cancer

  • Kim, Soung Min (Oral and Maxillofacial Microvascular Reconstruction Lab, Brong Ahafo Regional Hospital)
  • Received : 2016.09.08
  • Accepted : 2016.09.21
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Cervical cancer is the second most prevalent cancer among women, and it arises from cells that originate in the cervix uteri. Among several causes of cervical malignancies, infection with some types of human papilloma virus (HPV) is well known to be the greatest cervical cancer risk factor. Over 150 subtypes of HPV have been identified; more than 40 types of HPVs are typically transmitted through sexual contact and infect the anogenital region and oral cavity. The recently introduced vaccine for HPV infection is effective against certain subtypes of HPV that are associated with cervical cancer, genital warts, and some less common cancers, including oropharyngeal cancer. Two HPV vaccines, quadrivalent and bivalent types that use virus-like particles (VLPs), are currently used in the medical commercial market. While the value of HPV vaccination for oral cancer prevention is still controversial, some evidence supports the possibility that HPV vaccination may be effective in reducing the incidence of oral cancer. This paper reviews HPV-related pathogenesis in cancer, covering HPV structure and classification, trends in worldwide applications of HPV vaccines, effectiveness and complications of HPV vaccination, and the relationship of HPV with oral cancer prevalence.

Keywords

References

  1. Sun JR, Kim SM, Seo MH, Kim MJ, Lee JH, Myoung H. Oral cancer incidence based on annual cancer statistics in Korea. J Korean Assoc Oral Maxillofac Surg 2012;38:20-8. https://doi.org/10.5125/jkaoms.2012.38.1.20
  2. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Pineros M, et al. Cancer incidence in five continents Vol. X. Lyon: IARC Scientific Publication 164; 2014.
  3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  4. van der Marel J, Berkhof J, Ordi J, Torne A, Del Pino M, van Baars R, et al. Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion? Am J Surg Pathol 2015;39:496-504. https://doi.org/10.1097/PAS.0000000000000342
  5. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65. https://doi.org/10.1136/jcp.55.4.244
  6. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27. https://doi.org/10.1056/NEJMoa021641
  7. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27. https://doi.org/10.1016/j.virol.2004.03.033
  8. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, et al. Arrangement of L2 within the papillomavirus capsid. J Virol 2008;82:5190-7. https://doi.org/10.1128/JVI.02726-07
  9. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50. https://doi.org/10.1038/nrc798
  10. Rautava J, Syrjanen S. Biology of human papillomavirus infections in head and neck carcinogenesis. Head Neck Pathol 2012;6 Suppl 1:S3-15. https://doi.org/10.1007/s12105-012-0367-2
  11. Lizano M, Berumen J, Garcia-Carranca A. HPV-related carcinogenesis: basic concepts, viral types and variants. Arch Med Res 2009;40:428-34. https://doi.org/10.1016/j.arcmed.2009.06.001
  12. Cardoso JC, Calonje E. Cutaneous manifestations of human papillomaviruses: a review. Acta Dermatovenerol Alp Pannonica Adriat 2011;20:145-54.
  13. Orth G. Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol 2008;321:59-83.
  14. Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009;73:348-70. https://doi.org/10.1128/MMBR.00033-08
  15. Stoler MH. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 2000;19:16-28. https://doi.org/10.1097/00004347-200001000-00004
  16. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75. https://doi.org/10.1158/1055-9965.EPI-04-0551
  17. Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, de Sanjose S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009;62:870-8. https://doi.org/10.1136/jcp.2008.063149
  18. Campisi G, Panzarella V, Giuliani M, Lajolo C, Di Fede O, Falaschini S, et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions (review). Int J Oncol 2007;30:813-23.
  19. Femiano F. Papilloma virus. Review of the literature. Note II. Diagnosis and treatment. Minerva Stomatol 2000;49:179-86.
  20. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:622-35. https://doi.org/10.1067/moe.2001.115392
  21. Syrjanen K, Mantyjarvi R, Saarikoski S, Vayrynen M, Syrjanen S, Parkkinen S, et al. Factors associated with progression of cervical human papillomavirus (HPV) infections into carcinoma in situ during a long-term prospective follow-up. Br J Obstet Gynaecol 1988;95:1096-102. https://doi.org/10.1111/j.1471-0528.1988.tb06785.x
  22. Pfister H. Human papillomaviruses and skin cancer. Semin Cancer Biol 1992;3:263-71.
  23. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989;8:4099-105.
  24. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9. https://doi.org/10.1126/science.2157286
  25. Santoro V, Pozzuoli ML, Colella G. Role of human papilloma virus in precancerous and cancerous lesions of the oral cavity. Review of the literature. Minerva Stomatol 1997;46:595-601.
  26. Fornatora ML, Jones AC, Kerpel S, Freedman PD. It's time to modernize our approach to oral HPV lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:494-6. https://doi.org/10.1067/moe.2001.115128
  27. Park MW, Cho YA, Kim SM, Myoung H, Lee JH, Lee SK. Focal epithelial hyperplasia arising after delivery of metal-ceramic fixed dental prosthesis. J Adv Prosthodont 2014;6:555-8. https://doi.org/10.4047/jap.2014.6.6.555
  28. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC monographs on the evaluation of carcinogenic risks to humans: IARC monographs, volume 100B. A review of human carcinogens. B. Biological agents. Lyon: International Agency for Research on Cancer; 2012:278-80.
  29. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9. https://doi.org/10.1093/jnci/djn011
  30. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Metaanalysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010;2:15. https://doi.org/10.1186/1758-3284-2-15
  31. Bouda M, Gorgoulis VG, Kastrinakis NG, Giannoudis A, Tsoli E, Danassi-Afentaki D, et al. "High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. Mod Pathol 2000;13:644-53. https://doi.org/10.1038/modpathol.3880113
  32. Kojima A, Maeda H, Sugita Y, Tanaka S, Kameyama Y. Human papillomavirus type 38 infection in oral squamous cell carcinomas. Oral Oncol 2002;38:591-6. https://doi.org/10.1016/S1368-8375(01)00112-9
  33. Kim KS, Park SA, Ko KN, Yi S, Cho YJ. Current status of human papillomavirus vaccines. Clin Exp Vaccine Res 2014;3:168-75. https://doi.org/10.7774/cevr.2014.3.2.168
  34. Snow AN, Laudadio J. Human papillomavirus detection in head and neck squamous cell carcinomas. Adv Anat Pathol 2010;17:394-403. https://doi.org/10.1097/PAP.0b013e3181f895c1
  35. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407-20. https://doi.org/10.1093/jnci/djn025
  36. Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, Shan'gina O, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 2010;39:166-81. https://doi.org/10.1093/ije/dyp350
  37. Lajer CB, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS 2010;118:510-9. https://doi.org/10.1111/j.1600-0463.2010.02624.x
  38. Mishra R. Biomarkers of oral premalignant epithelial lesions for clinical application. Oral Oncol 2012;48:578-84. https://doi.org/10.1016/j.oraloncology.2012.01.017
  39. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 2008;37:1-10.
  40. Villa A, Villa C, Abati S. Oral cancer and oral erythroplakia: an update and implication for clinicians. Aust Dent J 2011;56:253-6. https://doi.org/10.1111/j.1834-7819.2011.01337.x
  41. Greer RO Jr, Meyers A, Said SM, Shroyer KR. Is p16(INK4a) protein expression in oral ST lesions a reliable precancerous marker? Int J Oral Maxillofac Surg 2008;37:840-6. https://doi.org/10.1016/j.ijom.2008.05.015
  42. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22. https://doi.org/10.1038/nrc2982
  43. Feller L, Wood NH, Khammissa RA, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med 2010;6:15. https://doi.org/10.1186/1746-160X-6-15
  44. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction--the first five years. Vaccine 2012;30 Suppl 5:F139-48. https://doi.org/10.1016/j.vaccine.2012.05.039
  45. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect 2016;144:449-68. https://doi.org/10.1017/S0950268815002198
  46. zur Hausen H, Gissmann L, Steiner W, Dippold W, Dreger I. Human papilloma viruses and cancer. Bibl Haematol 1975;(43):569-71.
  47. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251-7. https://doi.org/10.1016/0042-6822(91)90772-4
  48. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 1991;60:1445-56. https://doi.org/10.1016/S0006-3495(91)82181-6
  49. zur Hausen H. Papillomaviruses in the causation of human cancers: a brief historical account. Virology 2009;384:260-5. https://doi.org/10.1016/j.virol.2008.11.046
  50. Kumaraswamy KL, Vidhya M. Human papilloma virus and oral infections: an update. J Cancer Res Ther 2011;7:120-7. https://doi.org/10.4103/0973-1482.82915
  51. Syrjanen KJ, Pyrhönen S, Syrjanen SM, Lamberg MA. Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions. Br J Oral Surg 1983;21:147-53. https://doi.org/10.1016/0007-117X(83)90060-4
  52. Cox MF, Scully C, Maitland N. Viruses in the aetiology of oral carcinoma? Examination of the evidence. Br J Oral Maxillofac Surg 1991;29:381-7. https://doi.org/10.1016/0266-4356(91)90006-Q
  53. Murray M. Progress in preventing cervical cancer: updated evidence on vaccination and screening [Internet]. Seattle (WA): Outlook 2010;27(2)/Program for Appropriate Technology in Health (PATH) [cited 2016 Aug 27]. Available from: http://www.path.org/publications/files/RH_outlook_27_2.pdf.
  54. Recommended adult immunization schedule--United States, 2012 [Internet]. Atlanta (GA): Centers for Disease Control and Prevention [cited 2016 Aug 27]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a9.htm.
  55. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576-85. https://doi.org/10.1056/NEJMoa1010971
  56. Huygen F, Verschueren K, McCabe C, Stegmann JU, Zima J, Mahaux O, et al. Investigating reports of complex regional pain syndrome: an analysis of HPV-16/18-adjuvanted vaccine postlicensure data. EBioMedicine 2015;2:1114-21. https://doi.org/10.1016/j.ebiom.2015.07.003
  57. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723-39. https://doi.org/10.1586/14760584.6.5.723
  58. Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med 2015;4:614-33. https://doi.org/10.3390/jcm4040614
  59. Kols A, Sherris J. HPV vaccines: promise and challenges [Internet]. Seattle (WA): PATH [cited 2016 Aug 27]. Available from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.424.5575&rep=rep1&type=pdf.
  60. Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil. J Adolesc Health 2011;49:467-75. https://doi.org/10.1016/j.jadohealth.2011.07.003
  61. McNeil C. Who invented the VLP cervical cancer vaccines? J Natl Cancer Inst 2006;98:433. https://doi.org/10.1093/jnci/djj144
  62. Shi L, Sings HL, Bryan JT, Wang B, Wang Y, Mach H, et al. GARDASIL: prophylactic human papillomavirus vaccine development: from bench top to bed-side. Clin Pharmacol Ther 2007;81:259-64. https://doi.org/10.1038/sj.clpt.6100055
  63. Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J 2015;34:983-91. https://doi.org/10.1097/INF.0000000000000793
  64. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7. https://doi.org/10.1001/jama.2009.1201
  65. Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine 2015;33:6855-64. https://doi.org/10.1016/j.vaccine.2015.08.059
  66. Labadie J. Postlicensure safety evaluation of human papilloma virus vaccines. Int J Risk Saf Med 2011;23:103-12.
  67. Brotherton JM, Ogilvie GS. Current status of human papillomavirus vaccination. Curr Opin Oncol 2015;27:399-404. https://doi.org/10.1097/CCO.0000000000000211
  68. Brisson M, Laprise JF, Chesson HW, Drolet M, Malagon T, Boily MC, et al. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst 2015. doi: 10.1093/jnci/djv282.
  69. Bazan SB, de Alencar Muniz Chaves A, Aires KA, Cianciarullo AM, Garcea RL, Ho PL. Expression and characterization of HPV- 16 L1 capsid protein in Pichia pastoris. Arch Virol 2009;154:1609-17. https://doi.org/10.1007/s00705-009-0484-8
  70. Rybicki EP, Williamson AL, Meyers A, Hitzeroth II. Vaccine farming in Cape Town. Hum Vaccin 2011;7:339-48. https://doi.org/10.4161/hv.7.3.14263
  71. Majewski S, Jablonska S. Immunology of HPV infection and HPVassociated tumors. Int J Dermatol 1998;37:81-95. https://doi.org/10.1046/j.1365-4362.1998.00435.x
  72. Chang F. Role of papillomaviruses. J Clin Pathol 1990;43:269-76. https://doi.org/10.1136/jcp.43.4.269
  73. Tindle RW, Frazer IH. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr Top Microbiol Immunol 1994;186:217-53.
  74. Arya SC, Agarwal N. Extended coverage of HPV vaccination in middle-aged adults to prevent oropharyngeal cancers. Hum Vaccin Immunother 2012;8:959. https://doi.org/10.4161/hv.20043
  75. Ramqvist T, Dalianis T. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res 2011;31:1515-9.
  76. Matsushita K, Sasagawa T, Miyashita M, Ishizaki A, Morishita A, Hosaka N, et al. Oral and cervical human papillomavirus infection among female sex workers in Japan. Jpn J Infect Dis 2011;64:34-9.
  77. Zil-A-Rubab, Baig S, Siddiqui A, Nayeem A, Salman M, Qidwai MA, et al. Human papilloma virus--role in precancerous and cancerous oral lesions of tobacco chewers. J Pak Med Assoc 2013;63:1295-8.

Cited by

  1. Microarray technology for identification of human papilloma virus subtype in oropharyngeal squamous cell carcinoma vol.274, pp.12, 2016, https://doi.org/10.1007/s00405-017-4662-0
  2. Biochanin-A induces apoptosis and suppresses migration in FaDu human pharynx squamous carcinoma cells vol.38, pp.5, 2016, https://doi.org/10.3892/or.2017.5953
  3. Clinical diagnostic guidelines of allergic rhinitis: comprehensive treatment and consideration of special circumstances vol.60, pp.3, 2016, https://doi.org/10.5124/jkma.2017.60.3.257
  4. Novel DNA CHIP detects human papillomaviruses in tonsillar tumors vol.12, pp.9, 2016, https://doi.org/10.2217/fvl-2017-0053
  5. Identification of human papillomavirus (HPV) subtype in oral cancer patients through microarray technology vol.275, pp.2, 2016, https://doi.org/10.1007/s00405-017-4828-9
  6. Trends and Spatial Patterns of Oral Cancer Mortality in Ecuador, 2001–2016 vol.2018, pp.None, 2018, https://doi.org/10.1155/2018/6086595
  7. Association of the Human Bocavirus With Tonsil Squamous Cell Carcinomas vol.9, pp.None, 2016, https://doi.org/10.3389/fmicb.2018.02450
  8. Quantitative polymerase chain reaction‐based detection of HPV 16 E6 and E7 DNA in oral squamous cell carcinoma vol.47, pp.9, 2016, https://doi.org/10.1111/jop.12770
  9. Oncogenic high-risk human papillomavirus in patients with full denture vol.33, pp.None, 2016, https://doi.org/10.1590/1807-3107bor-2019.vol33.0091
  10. Role of Smoking-Mediated molecular events in the genesis of oral cancers vol.29, pp.9, 2016, https://doi.org/10.1080/15376516.2019.1646372
  11. Prevalence of human papillomavirus type 16 in persistent oral lesions arising in patients with tobacco, areca nut, and alcohol habits vol.16, pp.3, 2016, https://doi.org/10.1002/osi2.1022
  12. Patterns of Tobacco Use and its Relation to Oral Precancers and Cancers among Individuals Visiting a Tertiary Hospital in South India vol.21, pp.3, 2020, https://doi.org/10.5005/jp-journals-10024-2791
  13. The possible regions to design Human Papilloma Viruses vaccine in Iranian L1 protein vol.75, pp.5, 2020, https://doi.org/10.2478/s11756-019-00386-w
  14. What the general dental practitioner needs to know about HPV-related oropharyngeal malignancy vol.229, pp.6, 2016, https://doi.org/10.1038/s41415-020-2113-6
  15. Water-Pipe Smoking Exposure Deregulates a Set of Genes Associated with Human Head and Neck Cancer Development and Prognosis vol.8, pp.3, 2020, https://doi.org/10.3390/toxics8030073
  16. Cervical, anal and oral HPV detection and HPV type concordance among women referred for colposcopy vol.15, pp.1, 2016, https://doi.org/10.1186/s13027-020-00287-7
  17. Salivary detection of high-risk human papillomavirus 16 in oral squamous cell carcinoma using polymerase chain reaction in the South Indian population vol.17, pp.4, 2016, https://doi.org/10.4103/jcrt.jcrt_957_19
  18. Non-invasive saliva-based screening of high-risk Human Papilloma Virus 16 and 18 in healthy young adults and creating awareness about its vaccination vol.10, pp.1, 2016, https://doi.org/10.4103/jfmpc.jfmpc_1669_20
  19. Dysbiosis of Oral Microbiota During Oral Squamous Cell Carcinoma Development vol.11, pp.None, 2016, https://doi.org/10.3389/fonc.2021.614448
  20. Extracellular Vesicles in Cervical Cancer and HPV Infection vol.11, pp.6, 2016, https://doi.org/10.3390/membranes11060453